Infinity Pharmaceuticals Inc (INFI)
OTC PINK OTC PINK Primary Summary
Infinity Pharmaceuticals Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 2,600 | $5,850 | $20.8 | -$5,829.2 | -99.64% |
Infinity Pharmaceuticals Inc (INFI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Infinity Pharmaceuticals Inc ever had a stock split?
Infinity Pharmaceuticals Inc Profile
| Biotechnology Industry | Healthcare Sector | Vishal Mehta CEO | OTC PINK Exchange | 45665G303 CUSIP |
| US Country | 30 Employees | - Last Dividend | 13 Sep 2006 Last Split | 28 Jul 2000 IPO Date |
Overview
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical entity dedicated to crafting innovative treatments for cancer patients. With a focus on precision medicine, the company prioritizes the development of new medicinal options aimed at improving the lives of those battling this arduous disease. Founded in 1995, Infinity Pharmaceuticals has established its headquarters in Cambridge, Massachusetts, signifying its presence in one of the world's foremost biotech hubs. Over the years, the company has forged strategic alliances with other industry leaders, enhancing its research capabilities and expediting its drug development processes. Despite showcasing promising developments in its portfolio, Infinity Pharmaceuticals faced significant financial challenges, leading to a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware, as of September 29, 2023. This decision underscored the volatile nature of the biopharmaceutical sector, especially for companies in the clinical stage of drug development. On March 7, 2024, the company's reorganization plan was approved as a Chapter 11 liquidation, indicating a pivotal moment in its corporate trajectory.
Products and Services
- Eganelisib (IPI-549): This leading product candidate embodies Infinity Pharmaceuticals' dedication to pioneering immuno-oncology treatments. As an orally administered compound, eganelisib targets the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), a critical player in the immune system's cancer-fighting ability. Its mechanism of inhibiting PI3K-gamma is currently being evaluated in Phase 2 clinical trials for treating metastatic triple-negative breast cancer and urothelial cancer. Additionally, eganelisib is undergoing Phase 1/1b trials for various solid tumors, showcasing its potential versatility in combating cancer.
- Strategic Alliances for PI3K Inhibition: Infinity Pharmaceuticals has entered into a pivotal partnership with Intellikine, Inc., focusing on the discovery, development, and commercialization of pharmaceuticals targeting the delta and/or gamma isoforms of PI3K. This collaboration underscores the company's commitment to exploring the therapeutic potential of PI3K inhibition in cancer treatment.
- Collaboration with Verastem, Inc.: Through its cooperative efforts with Verastem, Inc., Infinity Pharmaceuticals aims to research, develop, commercialize, and manufacture duvelisib, alongside other products incorporating this compound. Duvelisib's focus on disrupting cancer cell survival signals represents another facet of Infinity's strategy in immuno-oncology.
- Hedgehog Inhibitor Program with PellePharm, Inc.: Marking another innovative venture, Infinity has partnered with PellePharm, Inc. to advance the development and commercialization of IPI-926. This clinical-stage product candidate, stemming from the company's hedgehog inhibitor program, highlights Infinity Pharmaceuticals' pursuit of new pathways in cancer treatment.
- Collaborations With Global Pharma Leaders: Among its strategic initiatives, Infinity Pharmaceuticals has established collaboration agreements with F. Hoffmann-La Roche Ltd. and Bristol Myers Squibb Company, further amplifying its research and development capabilities through these partnerships with leading pharmaceutical corporations.
